In 2019, Mesoblast Ltd (MSB) plans to work diligently with the U.S. Food and Drug Administration (FDA) to submit a rolling Biologics License Application for use of remestemcel-L in treating acute graft versus host disease (aGVHD) in children, and will execute on the product candidate’s market access and commercialization strategyhttp://crweworld.com/article/news-provided-by-globenewswire/930707/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-biotech-showcase-in-san-francisco
Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
-0.025(1.55%) |
Mkt cap ! $2.031B | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.57 | $6.345M | 3.987M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 44493 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 4159 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |